RecruitingNot applicableNCT06033248

Using Urine Samples to Identify Lung Cancer

The researchers are doing this study to test the ability of an animal biosensor platform (ABP) to detect NSCLC. Participants in this study will either be diagnosed with NSCLC, suspected to have NSCLC, or have not been diagnosed or suspected to have NSCLC. The ABP test uses laboratory animals that are trained to detect (by smell) different chemicals in urine. Studies show that people with lung cancer have unique chemicals in their urine that are not present in people without lung cancer, and researchers think these chemicals can be used to identify people with lung cancer without the need for invasive procedures (like biopsy).

Checked against the public recordLast updated Jul 21, 2026 · Source: ClinicalTrials.gov

StatusRecruiting
PhaseNot applicable
U.S. locations7
SponsorMemorial Sloan Kettering Cancer Center
01
Study overview

What this study is about

Purpose
Not specified
Study type
Observational
Phase
Not applicable
Sponsor
Memorial Sloan Kettering Cancer Center
Interventions being studied
Diagnostic Test: urine sample
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

03
Public criteria

Who may be able to participate

Inclusion Criteria: * Phase I (with NSCLC): Aged 18 to 90 years with histologically proven, previously untreated stage I, II, or IIIA NSCLC °Note: Single, monolateral nodule of at least 50% solid composition visible on a Chest CT scan that is suspicious for a primary neoplasm as confirmed by an official MSK radiologist read * Phase I (without NSCLC): Aged 18 to 90 years with patient confirmed absence of NSCLC * Phase II: Aged 18 to 90 years with suspected but undiagnosed stage I, II, or IIIA NSCLC by CT and/or PET scan criteria Exclusion Criteria: * Aged \<18 years * Lack of available results from low-dose CT * Receipt of radiation, chemotherapy, biological therapy, resection, or any other treatment for any cancer in the previous year * Pregnant (for women) * Taking drugs that affect the immune system * Chronic disease related to the immune system * Missing clinical data (i.e., current clinical staging)

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • Memorial Sloan Kettering Basking Ridge (All Protocol Activities)Basking Ridge, New Jersey
  • Memorial Sloan Kettering Monmouth (All Protocol Activities)Middletown, New Jersey
  • Memorial Sloan Kettering Bergen (All Protocol Activities)Montvale, New Jersey
  • Memorial Sloan Kettering Suffolk-Commack (All Protocol Activities)Commack, New York
  • Memorial Sloan Kettering Westchester (All Protocol Activities)Harrison, New York
  • Memorial Sloan Kettering Cancer Center (All Protocol Activities)New York, New York
  • Memorial Sloan Kettering Nassau (All Protocol Activities)Uniondale, New York

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Jul 21, 2026. Always confirm current availability with the study team.

View original record ↗